Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Chief Legal Officer | February 10, 2022 | February 15, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zentalis Pharmaceuticals, Inc.
Report date February 10, 2022 · Filed February 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,240 |
Ending reported balance
After 2022-02-14 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-02-10 · Grant · Acquired 16,405 · Balance 22,931 F1: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date. Row 2 · 2022-02-14 · Sale · Disposed 614 · Balance 22,317 F2: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.58 to $50.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2022-02-14 · Sale · Disposed 77 · Balance 22,240 F2: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F4: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.58 to $50.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.61 · Expires 2032-02-09 | Direct | 38,489 |
Reported balance
After 2022-02-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-02-10 · Grant · Acquired 38,489 · Balance 38,489 F5: The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
F2: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
F3: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.58 to $50.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.58 to $50.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2022 Filed Feb 15, 2022 02:10 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 77 | $50.75 | $3,907.53 |
DisclosureSEC source: 0001725160-22-000034 · wf-form4_164489099132680.xml · nonDerivative · entry 3 Pinto Alexis · CIK 0001819302 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,240 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.58 to $50.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 02:10 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 614 | $50.16 | $30,800.82 |
DisclosureSEC source: 0001725160-22-000034 · wf-form4_164489099132680.xml · nonDerivative · entry 2 Pinto Alexis · CIK 0001819302 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,317 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.58 to $50.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 02:10 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 38,489 | $0.00 Strike: $52.61 | $0.00 |
DisclosureSEC source: 0001725160-22-000034 · wf-form4_164489099132680.xml · derivative · entry 4 Pinto Alexis · CIK 0001819302 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,489 Underlying: Common Stock · 38,489 shares Expires 2032-02-09 F5 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 02:10 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 16,405 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-22-000034 · wf-form4_164489099132680.xml · nonDerivative · entry 1 Pinto Alexis · CIK 0001819302 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,931 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date. Read SEC document |
| October 25, 2021 Filed Oct 28, 2021 00:13 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $34.40 | $0.00 |
DisclosureSEC source: 0001725160-21-000206 · wf-form4_163537997775449.xml · derivative · entry 6 Pinto Alexis · CIK 0001819302 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,000 Underlying: Common Stock · 30,000 shares Expires 2030-08-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F6 · derivative.exercise_date: The options vest and become exercisable as to 25% of the total number of shares underlying the option on August 31, 2021 and as to the remaining 75% in 36 substantially equal monthly installments thereafter. Read SEC document |
| October 25, 2021 Filed Oct 28, 2021 00:13 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 300 | $78.85 | $23,655.00 |
DisclosureSEC source: 0001725160-21-000206 · wf-form4_163537997775449.xml · nonDerivative · entry 5 Pinto Alexis · CIK 0001819302 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,526 F1 · kind: The stock option exercise and sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. Read SEC document |
| October 25, 2021 Filed Oct 28, 2021 00:13 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 19,802 | $78.05 | $1,545,643.13 |
DisclosureSEC source: 0001725160-21-000206 · wf-form4_163537997775449.xml · nonDerivative · entry 4 Pinto Alexis · CIK 0001819302 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,826 F1 · kind: The stock option exercise and sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $77.59 to $78.44. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 25, 2021 Filed Oct 28, 2021 00:13 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 8,098 | $77.27 | $625,730.84 |
DisclosureSEC source: 0001725160-21-000206 · wf-form4_163537997775449.xml · nonDerivative · entry 3 Pinto Alexis · CIK 0001819302 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,628 F1 · kind: The stock option exercise and sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $76.59 to $77.58. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 25, 2021 Filed Oct 28, 2021 00:13 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,800 | $76.10 | $136,973.34 |
DisclosureSEC source: 0001725160-21-000206 · wf-form4_163537997775449.xml · nonDerivative · entry 2 Pinto Alexis · CIK 0001819302 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,726 F1 · kind: The stock option exercise and sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $75.57 to $76.53. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 25, 2021 Filed Oct 28, 2021 00:13 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | Exercise / conversionCommon Stock | 30,000 | $34.40 | $1,032,000.00 |
DisclosureSEC source: 0001725160-21-000206 · wf-form4_163537997775449.xml · nonDerivative · entry 1 Pinto Alexis · CIK 0001819302 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F2 · balance_after: Includes 276 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on September 30, 2021. Read SEC document |
| February 11, 2021 Filed Feb 17, 2021 00:04 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 18,750 | $0.00 Strike: $38.76 | $0.00 |
DisclosureSEC source: 0001725160-21-000040 · wf-form4_161352019880108.xml · derivative · entry 2 Pinto Alexis · CIK 0001819302 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2031-02-10 F2 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date. Read SEC document |
| February 11, 2021 Filed Feb 17, 2021 00:04 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-21-000040 · wf-form4_161352019880108.xml · nonDerivative · entry 1 Pinto Alexis · CIK 0001819302 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 01:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $34.40 | $0.00 |
DisclosureSEC source: 0001725160-20-000020 · wf-form4_159900936053889.xml · derivative · entry 1 Pinto Alexis · CIK 0001819302 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2030-08-30 F1 · derivative.exercise_date: The options vest and become exercisable as to 25% of the total number of shares underlying the option on August 31, 2021 and as to the remaining 75% in 36 substantially equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.